Revance Therapeutics, Inc. is a privately held biopharmaceutical company developing products that will change the way that drugs are delivered.
The company's proprietary TransMTS® technology has demonstrated the ability to carry active levels of drug across the skin to deliver at specific and targeted depths - enabling topical delivery of macromolecules and eliminating needles.
Our lead investigational product utilizing the TransMTS technology is a physician-applied topical botulinum toxin type A (BoNTA) product being developed for cosmetic and therapeutic indications (RT001). Eliminating needles from treatment with BoNTA could significantly expand the market by removing many of the barriers to entry.
Revance has the exclusive rights to a portfolio of highly purified BoNTA proteins for use across all dose forms for all indications worldwide.
Our proprietary BoNTA proteins and TransMTS technology have applications beyond the initial dermatology focus: our pipeline includes research programs in other therapeutic areas, and we are pursuing licensing opportunities for use of TransMTS with additional compounds.